Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Simcere Out-Licenses Autoimmune Candidate to Almirall in $507 Million Deal

publication date: Sep 29, 2022

Simcere Pharma of Nanjing announced a $507 million out-licensing to Spain’s Almirall for ex-China rights to a biologic autoimmune candidate. SIM0278 in an IND-ready interleukin 2 mutant fusion protein (IL-2 mu-Fc) that activates regulatory T cells developed by Simcere's protein engineering platform. Almirall, a dermatology biopharma, will make a $15 million upfront payment to Simcere and up to $492 million in milestones, plus royalties. Almirall will have rights for all indications outside of Greater China. For Almirall, probable indications are skin diseases, including psoriasis, atopic dermatitis and alopecia areata. More details....

Stock Symbols: (HK: 2096) (BME: ALM)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China